Cobham has been awarded a contract for the supply of its Deployable Oxygen Generation System-Medium (DOGS-M) systems to the US Air Force (USAF).

Awarded by the US Air Combat Command (ACC), the contract is initially valued at $3m, but is expected to reach a maximum potential value of $20m during the course of the programme to efficiently address the specific requirements of customers across the globe.

"The DOGS-M is a US Food and Drug Administration (FDA) approved oxygen concentration system."

Commenting on the system, Cobham Life Support president Kelly Coffield said the DOGS-M system represents the new standard in point-of-use medical oxygen generation and cylinder recharging capability, due to its rugged, portable and reliable nature.

”The availability of high volume medical oxygen provides the medical practitioner with flexibility for respiratory treatment in the field,” Coffield added.

The systems delivered as part of the contract are expected to be forward deployed by the air force at its mature and immature Joint Operating Areas (JOAs) worldwide to support different military operations conducted for longer duration under challenging environments.

The DOGS-M is a US Food and Drug Administration (FDA) approved oxygen concentration system designed to enable direct administration of therapeutic oxygen to wounded soldiers in the battlefield.

Capable of generating USP 93% gaseous oxygen at 120LPM, the cost-efficient system can persistently monitor all critical performance related functions, including inlet air temperature and pressure, as well as oxygen product concentration and pressure.

DOGS-M has already demonstrated its compatibility in recharging the mobile oxygen storage tank (MOST) systems and interfacing with the patient oxygen delivery system (PODS). It also serves as an alternative to existing cylinders by reducing storage space and logistics costs.

Image: The DOGS-M system can save soldiers’ lives during longer duration operations. Photo courtesy of Cobham.